We work alongside your existing treatment plan to enhance your mental health journey.

By leveraging the latest neurotechnologies, such as TMS (Transcranial Magnetic Stimulation), ECT (Electroconvulsive Therapy), and Spravato, patients often achieve faster remission from psychiatric symptoms compared to medication alone. These treatments also help maintain long-term stability more effectively than traditional psychiatric medications.

TMS and ECT specifically target and modulate dysfunctional brain circuits, providing therapeutic benefits tailored to each patient’s needs.

To refer a patient or discuss treatment options, contact us today by phone or email.

Phone: (602) 824-8404

Email: admin@interpsychaz.com

Refer a Patient

These advanced technologies target conditions linked to brain network dysfunction, including depression, anxiety, obsessive-compulsive disorder (OCD), substance abuse, chronic pain syndromes, and certain movement disorders.

Ongoing research is expanding their clinical applications, with future potential in neurology, neurosurgery, and pain management.

Our shared goal is to provide the highest quality care to alleviate mental health symptoms. By incorporating these innovative treatments, we offer patients more options and a greater opportunity to heal.

Refer a Patient

Our Modalities

About TMS Therapy

Transcranial Magnetic Stimulation (TMS) is an FDA-approved treatment for Major Depressive Disorder (MDD) since 2008, with expanded approval in 2013 for pain relief associated with certain migraine headaches. Unlike Electroconvulsive Therapy (ECT), TMS is noninvasive, does not induce seizures, and allows patients to remain awake during the procedure. The treatment is well-tolerated, with mild side effects such as headaches, muscle twitches, and localized discomfort at the stimulation site.

TMS is typically administered four to five times per week for four to six weeks.

Research-backed protocols have been developed for TMS applications in treating Obsessive-Compulsive Disorder (OCD), anxiety disorders, and other off-label conditions, including:

  • Anxiety comorbid with MDD
  • Post-Traumatic Stress Disorder (PTSD)
  • Chronic pain/fibromyalgia
  • Panic disorder
  • Cocaine addiction
  • Tinnitus
  • Smoking cessation

TMS is a valuable treatment option for individuals struggling with MDD as defined by the DSM-V. While it may be considered a first-line treatment, it is most commonly recommended for patients who have not achieved remission after trying one or more antidepressant medications.

Theta Burst Stimulation

The Horizon 3® TMS system provides enhanced treatment versatility, offering multiple therapy options, including:

  • Repetitive TMS (rTMS) – Standard 37.5-minute session
  • Accelerated TMS – 19-minute session
  • Intermittent Theta Burst Stimulation (iTBS) – A rapid 3-minute session with FDA clearance

This range of treatment durations allows clinicians to tailor therapy based on individual patient needs.

StimGuide® 3-D Positioning System

The Horizon® Performance with StimGuide® Navigated TMS Package enhances treatment precision by ensuring accurate, consistent coil positioning across four key parameters:

  1. Contact – Proper coil placement
  2. XY Location – Precise targeting
  3. Tilt – Optimal angle adjustment
  4. Rotation – Consistent positioning for every session

Additionally, the E-z MT® motor threshold determination process simplifies calibration, improving treatment accuracy and efficiency.

Electroconvulsive Therapy (ECT)

ECT is a well-established psychiatric treatment involving brief electrical stimulation of the brain while the patient is under anesthesia. A psychiatrist, along with an anesthesia team and nursing staff, administers the procedure in a controlled medical setting.

Since its introduction in the 1940s, ECT has evolved into a highly effective and safe intervention for severe major depression, showing substantial improvement in approximately 80% of patients. It is also used to treat:

  • Bipolar disorder
  • Schizophrenia
  • Catatonia

ECT is particularly beneficial for psychiatric emergencies, including:

  • Medically compromised catatonia
  • Active suicidal ideations requiring rapid symptom relief

ECT is most effective when combined with psychiatric medications and psychotherapy. In some cases, maintenance ECT may be recommended to prevent relapse after achieving symptom remission.

Spravato Esketamine Therapy

SPRAVATO® is the first FDA-approved nasal spray antidepressant, used alongside oral antidepressants to treat:

  • Treatment-resistant depression (TRD) – For adults who have not responded to at least two different antidepressants at adequate doses and durations.
  • Major Depressive Disorder (MDD) with suicidal thoughts or actions – Offering a rapid reduction in symptoms for those experiencing acute distress.

Unlike traditional antidepressants, which can take weeks to produce noticeable effects, Spravato® works within 24 hours by targeting brain cells directly, offering fast relief for severe depressive symptoms.